ENHANCE Trademark

Trademark Overview

On Tuesday, July 25, 2023, a trademark application was filed for ENHANCE with the United States Patent and Trademark Office. The USPTO has given the ENHANCE trademark a serial number of 98100825. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Friday, February 14, 2025. This trademark is owned by EXCELLTHERA INC.. The ENHANCE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Platform as a service (PAAS) featuring software for administering the out-licensing of small molecules for use in cell and gene therapy to process cell expansion, rejuvenation and engineering
enhance

General Information

Serial Number98100825
Word MarkENHANCE
Filing DateTuesday, July 25, 2023
Status653 - SUSPENSION LETTER - MAILED
Status DateFriday, February 14, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPlatform as a service (PAAS) featuring software for administering the out-licensing of small molecules for use in cell and gene therapy to process cell expansion, rejuvenation and engineering

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, August 23, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEXCELLTHERA INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMontreal, Quebec H3T1J4
CA

Trademark Events

Event DateEvent Description
Friday, July 28, 2023NEW APPLICATION ENTERED
Friday, April 5, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 27, 2024ASSIGNED TO EXAMINER
Friday, April 5, 2024NON-FINAL ACTION WRITTEN
Friday, April 5, 2024NON-FINAL ACTION E-MAILED
Friday, May 17, 2024EXAMINERS AMENDMENT -WRITTEN
Friday, May 17, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, April 17, 2024ASSIGNED TO EXAMINER
Friday, May 17, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, May 17, 2024EXAMINER'S AMENDMENT ENTERED
Friday, May 17, 2024SUSPENSION LETTER WRITTEN
Friday, May 17, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, May 17, 2024LETTER OF SUSPENSION E-MAILED
Friday, January 31, 2025SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Monday, February 3, 2025INQUIRY TO SUSPENSION E-MAILED
Monday, February 3, 2025NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, February 3, 2025SUSPENSION INQUIRY WRITTEN
Monday, February 10, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, February 13, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 13, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 13, 2025ASSIGNED TO LIE
Friday, February 14, 2025LETTER OF SUSPENSION E-MAILED
Friday, February 14, 2025SUSPENSION LETTER WRITTEN
Friday, February 14, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

Related Keywords

enhance cell therapy gene process expansion engineering rejuvenation molecules small paas